cGKI Antibodies

Santa Cruz Biotechnology delivers a wide array of cyclic GMP-dependent protein kinase I (cGKI) monoclonal antibodies for research in understanding biological processes. The monoclonal antibodies are suitable for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). cGKI plays a crucial role in mediating the effects of nitric oxide and cyclic GMP signaling pathways, which are essential for regulating vascular smooth muscle relaxation, neuronal signaling, and various cellular processes. The proper functioning of cGKI is vital for cardiovascular health and has implications in conditions such as hypertension and heart failure. Researchers investigating cGKI can explore its involvement in signal transduction pathways and cellular responses. Understanding cGKI function helps reveal its significance in maintaining cardiovascular homeostasis and potential therapeutic interventions. Current studies focus on how cGKI influences various physiological processes and its potential as a therapeutic target. Santa Cruz Biotechnology monoclonal antibodies enable researchers worldwide to advance scientific understanding of cGKI's role in health and disease.